Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:CRDL NASDAQ:CTNM NASDAQ:HELP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.20-0.2%$8.14$6.05▼$14.51$530.36M1.74564,787 shs551,914 shsCRDLCardiol Therapeutics$1.20+3.9%$1.13$0.88▼$1.71$133.11M0.74820,570 shs992,449 shsCTNMContineum Therapeutics$14.16+2.2%$13.56$5.07▼$16.91$518.17M0.7272,633 shs210,882 shsHELPCybin$7.60-1.3%$5.60$3.76▼$9.12$538.03M0.621.61 million shs860,711 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.24%-0.73%+2.05%-16.50%+7.75%CRDLCardiol Therapeutics+3.90%-3.23%+15.38%-8.40%-21.57%CTNMContineum Therapeutics+2.16%+1.87%+0.07%+17.61%+156.99%HELPCybin-1.30%-6.17%+16.69%+54.79%+759,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.20-0.2%$8.14$6.05▼$14.51$530.36M1.74564,787 shs551,914 shsCRDLCardiol Therapeutics$1.20+3.9%$1.13$0.88▼$1.71$133.11M0.74820,570 shs992,449 shsCTNMContineum Therapeutics$14.16+2.2%$13.56$5.07▼$16.91$518.17M0.7272,633 shs210,882 shsHELPCybin$7.60-1.3%$5.60$3.76▼$9.12$538.03M0.621.61 million shs860,711 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.24%-0.73%+2.05%-16.50%+7.75%CRDLCardiol Therapeutics+3.90%-3.23%+15.38%-8.40%-21.57%CTNMContineum Therapeutics+2.16%+1.87%+0.07%+17.61%+156.99%HELPCybin-1.30%-6.17%+16.69%+54.79%+759,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.46Hold$15.4288.01% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50608.33% UpsideCTNMContineum Therapeutics 2.40Hold$20.0041.24% UpsideHELPCybin 3.00Buy$45.25495.39% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, ARVN, HELP, and CTNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/27/2026HELPCybin Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.007/17/2026CTNMContineum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026CRDLCardiol Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/13/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026ARVNArvinas StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.005/26/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/19/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026CTNMContineum Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$14.00 ➝ $16.00(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.01N/AN/A$6.76 per share1.21CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ACTNMContineum Therapeutics$50M10.59N/AN/A$6.99 per share2.03HELPCybinN/AN/AN/AN/A$4.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)CTNMContineum Therapeutics-$59.98M-$1.95N/AN/AN/AN/A-27.09%-25.64%8/4/2026 (Estimated)HELPCybin-$148M-$4.23N/AN/AN/AN/A-68.27%-58.26%N/ALatest CRDL, ARVN, HELP, and CTNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CRDLCardiol Therapeutics-$0.08N/AN/AN/AN/AN/A8/5/2026Q2 2026ARVNArvinas-$0.24N/AN/AN/A$60.71 millionN/A8/4/2026Q2 2026CTNMContineum Therapeutics-$0.46N/AN/AN/AN/AN/A5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/5/2026Q1 2026CTNMContineum Therapeutics-$0.55-$0.39+$0.16-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.445.44CRDLCardiol TherapeuticsN/A4.394.39CTNMContineum TherapeuticsN/A38.0038.00HELPCybinN/A9.529.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CRDLCardiol Therapeutics12.49%CTNMContineum TherapeuticsN/AHELPCybin17.94%Insider OwnershipCompanyInsider OwnershipARVNArvinas7.30%CRDLCardiol Therapeutics5.25%CTNMContineum Therapeutics7.90%HELPCybin15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million59.81 millionOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableCTNMContineum Therapeutics3137.39 million34.43 millionN/AHELPCybin5069.87 million59.39 millionN/ACRDL, ARVN, HELP, and CTNM HeadlinesRecent News About These CompaniesCybin Inc. (NASDAQ:HELP) Receives Average Recommendation of "Buy" from AnalystsJuly 27 at 10:13 AM | marketbeat.comCybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector AssumptionsJuly 25, 2026 | finance.yahoo.comHelus Pharma Announces Completion of Enrollment in Phase 3 APPROACH Study of HLP003 in Major Depressive DisorderJuly 21, 2026 | quiverquant.comQHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of ScheduleJuly 21, 2026 | globenewswire.comCybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 MillionJuly 17, 2026 | finance.yahoo.comHelus Pharma Raises US$50 Million to Advance Novel Mental Health PipelineJuly 17, 2026 | tipranks.comIs Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?July 15, 2026 | finance.yahoo.comWhat is HC Wainwright's Forecast for Cybin FY2027 Earnings?July 13, 2026 | marketbeat.comWhat is HC Wainwright's Estimate for Cybin Q1 Earnings?July 10, 2026 | marketbeat.comHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsJune 29, 2026 | globenewswire.comCybin: A Speculative Bet On Their Pivotal Depression ReadoutJune 27, 2026 | seekingalpha.comCybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?June 26, 2026 | finance.yahoo.comHelus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug PipelineJune 25, 2026 | tipranks.comHelus Pharma™ Announces Closing of US$50 Million Underwritten OfferingJune 25, 2026 | globenewswire.comHelus Pharma™ Announces US$50 Million Underwritten OfferingJune 24, 2026 | globenewswire.comHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressJune 24, 2026 | globenewswire.comHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives ConferenceJune 11, 2026 | globenewswire.comHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New YorkJune 1, 2026 | globenewswire.comCORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 30, 2026 | globenewswire.comHelus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceApril 30, 2026 | globenewswire.comHelus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20263 Rare-Earth ETFs That Help Investors Balance Exposure and RiskBy Chris Markoch | July 12, 2026Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?By Chris Markoch | July 18, 2026CRDL, ARVN, HELP, and CTNM Company DescriptionsArvinas NASDAQ:ARVN$8.20 -0.02 (-0.24%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$8.20 0.00 (0.00%) As of 07/28/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cardiol Therapeutics NASDAQ:CRDL$1.20 +0.05 (+3.90%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$1.20 0.00 (-0.42%) As of 07/28/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Contineum Therapeutics NASDAQ:CTNM$14.16 +0.30 (+2.16%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$14.12 -0.04 (-0.28%) As of 07/28/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Cybin NASDAQ:HELP$7.60 -0.10 (-1.30%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$7.54 -0.06 (-0.84%) As of 07/28/2026 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
